SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing a massive surge in investor interest following optimistic executive commentary on the REGAL Phase 3 trial data, which suggests superior survival outcomes compared to current standards of care. The community is actively discussing an imminent short squeeze and institutional accumulation as they await the pivotal 80th trial event, fueling bullish sentiment around the company's potential to disrupt the oncology market.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is experiencing significant volatility as investors weigh strong delivery milestones and institutional accumulation against bearish sentiment regarding Chinese EV sector headwinds and broader market skepticism. The community remains deeply divided, with bulls highlighting the long-term potential of the battery-swap infrastructure and upcoming earnings, while bears point to persistent share price stagnation and ongoing concerns over profitability and dilution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the FDA's acceptance of its supplemental Biologics License Application for ANKTIVA, triggering a PDUFA date of January 6, 2027, as investors discuss the stock's significant market expansion potential into papillary bladder cancer. The community is actively debating the significance of the upcoming ASCO abstract releases and the company's competitive standing against major pharma alternatives while highlighting the stock's high short interest and institutional accumulation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently the primary focus for market participants as investors brace for high-stakes earnings that could define the near-term trajectory for AI-linked stocks and broader market sentiment. The community is heavily split, with intense debate over whether the stock will break out or trigger a sell-the-news reaction, while many are closely watching for updates on Blackwell shipments and forward guidance to validate the ongoing AI infrastructure spending thesis.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token (VVV) is generating significant momentum as the community focuses on its privacy-focused AI utility and a series of strategic exchange listings. Investors are closely tracking deflationary tokenomics, including ongoing buybacks and burns, while many discuss the potential for future price appreciation driven by the project's growing AI ecosystem and low circulating supply.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

Investors are closely monitoring e.l.f. Beauty ahead of its earnings report, debating whether the stock is an undervalued opportunity due to its resilient consumer base and growth potential or a falling knife amid insider selling and broader market volatility. The community is actively discussing potential catalysts like tariff refunds and expansion strategies while navigating a high-stakes psychological tug-of-war between retail bulls and perceived institutional manipulation.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is trending as it takes the lead-left role on the highly anticipated SpaceX IPO, which market participants are closely watching due to the company's massive reported valuation. Meanwhile, the community is actively debating the stock's technical performance and broader institutional influence, including its role in major AI-driven partnerships and institutional capital flows.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is facing significant volatility ahead of its upcoming earnings report, with shareholders intensely debating the company's long-term potential as a pre-revenue energy player versus concerns over share dilution and high cash burn. The community remains deeply divided, with bulls pointing to high-profile AI and defense partnerships and upcoming criticality milestones as major catalysts, while bears warn of the company's lack of revenue and aggressive equity offerings.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar Automotive Holding UK PLC

Polestar is trending as investors weigh mixed Q1 delivery results and persistent cash burn concerns against a new equity financing deal aimed at bolstering liquidity. Community discussion remains polarized, with bulls highlighting the brand's expanding retail footprint and upcoming model offensive while bears point to negative gross margins and significant share dilution.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending due to heightened volatility following conflicting market expectations regarding a potential aircraft order from China during the presidential summit. While the community is actively debating the impact of a confirmed 200-jet deal versus prior 500-plane rumors, investors are largely focused on the company's massive long-term backlog and the ongoing operational turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update PR Newswire SOMERVILLE, Mass., May 7, 2026 SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials...

Generate Biomedicines (NASDAQ:GENB) Hits New 1-Year High  - Should You Buy?

Generate Biomedicines (NASDAQ:GENB) Reaches New 52-Week High - Time to Buy...

Generate Biomedicines (NASDAQ:GENB) Trading Up 8.1% - Should You Buy?

Generate Biomedicines (NASDAQ:GENB) Shares Up 8.1% - Still a Buy...

Generate Biomedicines Inc (NASDAQ:GENB) Given Consensus Rating of "Moderate Buy" by Analysts

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings...

Research Analysts Set Expectations for GENB Q1 Earnings

Generate Biomedicines Inc (NASDAQ:GENB - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for Generate Biomedicines in a report issued on Monday, April 13th. HC...

Generate Biomedicines (NASDAQ:GENB) Shares Up 7%  - What's Next?

Generate Biomedicines (NASDAQ:GENB) Trading Up 7% - Time to Buy...

Generate Biomedicines (NASDAQ:GENB) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright initiated coverage on Generate Biomedicines in a research note on Monday. They issued a "buy" rating and a $16.00 price objective on the stock...

Generate Biomedicines (NASDAQ:GENB) Trading Down 6.9% - Time to Sell?

Generate Biomedicines (NASDAQ:GENB) Shares Down 6.9% - Time to Sell...

Generate Biomedicines Inc's Quiet Period To End on April 8th (NASDAQ:GENB)

Generate Biomedicines' (NASDAQ:GENB - Get Free Report) quiet period will end on Wednesday, April 8th. Generate Biomedicines had issued 25,000,000 shares in its IPO on February 27th. The total size of...

Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Recommendation of "Buy" from Analysts

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) has received an average recommendation of "Buy" from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year...

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

GENB
Generate Biomedicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest GENB News

GENBGenerate Biomedicines Inc